Pharma BD Deal Intelligence
Chairman Staf Van Reet: 'This transaction, when completed, will create significant shareholder value. This offer is a further remarkable milestone in Movetis'…
Shire's Mike Cola called Movetis 'a highly complementary fit for our GI business unit'; Shire estimates Resolor peak sales above €300M, citing strong patent…
Movetis was a 2006 J&J spinoff that took Resolor through EU approval in 30 countries and a 2009 IPO before Shire's €428M takeout — a fast specialty-pharma…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Shire to acquire Movetis at €19/share cash, valuing equity at €428M (~$565M). Adds Belgian GI specialist with Resolor. Closed October 2010 with 99.21% shares tendered.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Movetis NV (this deal) | 2010 | $565M | 37 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
← Browse all deals · How we score deals
More: 2010 deals · Shire plc deals · Gastroenterology deals